Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Theralase Technologies ( (TSE:TLT) ) has issued an announcement.
Theralase Technologies has released its audited consolidated financial statements for the year ending December 31, 2024. The company will hold a conference call on March 19, 2025, to discuss the financial and operational results, providing stakeholders with insights into its performance and future prospects.
More about Theralase Technologies
Theralase Technologies Inc. is a clinical stage pharmaceutical company focused on the research and development of light, radiation, sound, and drug-activated small molecules. The company’s primary aim is to create formulations for the safe and effective destruction of various cancers, bacteria, and viruses.
YTD Price Performance: -16.07%
Average Trading Volume: 110,057
Technical Sentiment Consensus Rating: Hold
Current Market Cap: C$58.23M
See more data about TLT stock on TipRanks’ Stock Analysis page.